ABOUT CONCENTER BioPharma LTD
CONCENTER BioPharma
IS A SUBSSIDIARY OF SILKIM Pharma LTD
which developed a novel, protected PLATFORM of drugs for proven treatments of multiple indications.
Our PLATFORM is the result of extensive investigation of animal models of human diseases.
Members of our PLATFORM act as:
- Potent anti-inflammatory agents.
- Strong iron chelating agents, and Anti-biotic agents.
These Modes of Action jointly assist in treating the causes and/or symptoms of multiple indications.
Our PLATFORM enables accelerated expansion from one proven product to another without having to rediscover
and re-create a specific underlying technology for each product.
Concenter BioPharma is committed to developing and delivering proven therapies that work harmoniously with
the human body and advance the treatment landscape for people with life-threatening diseases.
Clinical Applications being developed in Concenter BioPharma focus on TYPE 2 DIABETES - demonstrated in
diet-induced diabetes (Sand Rat) by markedly inhibiting the appearance and the degree of hyperglycemia, arresting the conversion of insulin-resistance state to fully-blown diabetes; attenuating cataract formation and diabetes-induced retinopathy.
Clinical Applications being developed in Concenter BioPharma focus on TYPE 2 DIABETES demonstrated in diet-induced diabetes (Sand Rat) by markedly inhibiting the appearance and the degree of hyperglycemia, arresting the conversion of insulin-resistance state to fully-blown diabetes; attenuating cataract formation and diabetes-induced retinopathy.
TYPE 2 DIABETES
Global Epidemic costing over $850 Billion/Year. In many countries - 1 out of 3 people is either Diabetic or
Pre-Diabetic! Over 450 Million people worldwide currently have diabetes; 12% of Global health expenditure is spent on diabetes. In the USA - >30 Million have diabetes and an additional 89 Million have Pre-Diabetes, over 4,100 new patients are diagnosed DAILY; $322 Billion per year is spent on diabetes, 20% of healthcare costs go to caring for people with diabetes! In China (WHO data), over 10% of all adults – about 110 million people – currently live with diabetes; rates of Type 2 diabetes in China have exploded in the last couple of decades; almost half of all adults in China – close to 500 million people – have prediabetes.
During the development of the PLATFORM the following milestones have already been realized:
-
Synthesis of several therapeutic agents – members of the PLATFORM
-
Chemical characterization of the structure and properties of the two therapeutic agents
-
Biological characterization of the therapeutic activities of the therapeutic agents in an animal model of inflammatory skin diseases
-
Biological characterization of the therapeutic activities of the therapeutic agents in an animal model of nutritionally induced diabetes
-
Biological characterization of the therapeutic activities of the therapeutic agents in an animal model of asthma
-
Identification of molecular target of the therapeutic agents via 3 simultaneous modes of action
-
Identification of NEW members of the PLATFORM of therapeutic agents and partial characterization of their chemical properties and biological activities
-
Biological characterization of the therapeutic activities of the therapeutic agents in an animal model of spinal cord injury
-
8 patents